To determine whether unihemispheral hemodynamic failure is independently associated with cognitive impairment among participants in the National Institute of Neurological Disorders and Stroke-sponsored, multicenter, randomized clinical trial, Randomized Evaluation of Carotid Occlusion and Neurocognition (RECON).
Carotid artery disease has been associated with cognitive impairment, [1] [2] [3] [4] but correlations with quantitative measures of cerebral blood flow (CBF) have been rare. The Randomized Evaluation of Carotid Occlusion and Neurocognition (RECON) is an National Institute of Neurological Disorders and Stroke-sponsored, multicenter, randomized, controlled clinical trial that is an ancillary study of the Carotid Occlusion Surgery Study (COSS). RECON was designed to test the hypothesis that surgical anastomosis of the extracranial superficial temporal artery to the intracranial middle cerebral artery (EC-IC bypass) when added to best medical therapy, can improve or preserve cognitive function at 2 years in patients with symptomatic internal carotid artery (ICA) occlusion and stage II hemodynamic failure better than the best medical therapy alone. The parent study, COSS, tested the hypothesis that EC-IC bypass would significantly reduce the risk of subsequent stroke. 5 Both COSS and RECON assessed hemispheral hemodynamic failure by identifying increased oxygen extraction fraction (OEF) by PET on the side of occlusion.
Reported here are the results of the baseline cognitive testing of the RECON cohort, comparing cognitive function in those who had unihemispheral cerebral hypoperfusion with a control group of clinically identical patients with carotid occlusion but without increased OEF. We took advantage of the 2-step randomization process in the study design to include this subgroup of enrolled but not randomized patients to serve as controls. Our data represent an advance over previous studies in obtaining quantitative blood flow data, measuring cognitive impairment with a disease-specific cognitive battery, and using an appropriately matched control group.
METHODS Subjects. Patients who met the inclusion criteria
of symptomatic carotid artery occlusion (hemispheral TIA or minor stroke) Ͻ120 days before enrollment were enrolled into RECON between 2004 and 2009. Symptoms had to have been attributable to the carotid occlusion, and patients had to have a Barthel Index Ն12/20 at the time of enrollment. Nonatherosclerotic causes of carotid occlusion were excluded based on all available clinical data. TIA was defined clinically as having no residual deficit after 24 hours. MRI was not available in all patients and so was not used in the definition of TIA. All enrolled patients underwent a PET scan to measure OEF. Status of collateral arteries was not assessed as part of the protocol. Patients were eligible for randomization to one of the treatment arms if they had asymmetrically increased OEF by PET (OEF ratio Ͼ1.13), indicating stage II hemodynamic failure on the side of occlusion. Those who had an OEF ratio Յ1.13 were not randomized and went no further in the study but were included in the current analysis as control subjects. The PET threshold of 1.13 was determined by a prospective natural history study, the St. Louis Carotid Occlusion Study, which examined thresholds of OEF associated with a higher rate of subsequent stroke. 6 Details of the PET protocol are published elsewhere. 5 Additional exclusion criteria for the RECON study were prior clinical diagnosis of dementia due to any cause, education level less than grade 4, or any neurologic deficit that prevented acquisition of informed consent. Thus, the study group includes no subjects who would be more impaired than a level equivalent to mild cognitive impairment, and some might be normal. The PET-positive patients were compared with the 28 RECON-enrolled patients who met all clinical and radiographic inclusion and exclusion criteria but were not randomized because they had no OEF asymmetry (PET-negative patients).
Standard protocol approvals, registrations, and patient consents. All patients provided informed consent. The study was approved by the Columbia University Institutional Review Board.
Neurocognitive testing. Patients underwent a 1-hour neuro-
cognitive battery consisting of 14 standardized neuropsychological tests, administered by a neuropsychologist or trained technician. The battery was designed to assess left hemisphere function, right hemisphere function, and global function. All tests had published, age-adjusted norms. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] All patients were administered all 14 neurocognitive tests. The order of test administration remained constant, accommodating the delays required for recall intervals and minimizing stimulus interference in memory tasks. The test battery is summarized in table 1.
Because hemodynamic failure in the hemisphere ipsilateral to the symptomatic carotid occlusion was hypothesized to affect predominantly functions associated with that hemisphere, as well as global cognitive function that would also use that hemisphere, composite scores were generated for each patient based on the hemisphere of interest: We first transformed the raw test scores for each patient into test-specific z scores for each test in the battery, derived from published norms. We then calculated a composite z score based on the average z score for the appropriate set of tests for each patient (sum of the relevant z scores divided by the number of tests included). For patients with left carotid occlusion, left hemisphere and global test scores were used; for patients with right carotid occlusion, right hemisphere and global test scores were used.
Statistical analysis. A multivariable regression was performed
comparing patients with a PET OEF ratio Ͼ1.13 with those with an OEF ratio Յ1.13, stratifying by TIA vs stroke as the qualifying event. This preplanned analysis was formulated to enable us to focus on the patients with TIA, a group in which the likely cognitive effects of stroke, per se, would not confound the hypothesized effects of hypoperfusion. Thus, for this baseline study we postulated that any potential hypoperfusionattributable effects on cognition would be seen best in those who qualified for the study (PET-positive) with TIA only. Our dependent variable was the composite neurocognitive z score, which was the only outcome measure of cognitive function in 
RESULTS
A total of 71 patients, 32 with TIA as the qualifying event and 39 qualifying with mild to moderate stroke, met the enrollment criteria for this study and had complete data. There were no differences in demographic, clinical, or radiologic characteristics between the PET-positive (OEF ratio Ͼ1.13) and PET-negative (OEF ratio Յ1.13) patients, except for PET OEF asymmetry and previous stroke (table 2) . The unadjusted average neurocogni-tive z score was Ϫ1.45 below the normative mean for the PET-positive and Ϫ1.25 for the PET-negative patients, indicating cognitive impairment among both groups (with and without hemodynamic failure) but no significant difference between them ( p ϭ 0.641).
In the multivariable regression analysis, after adjustment for age, education, side of occlusion, and previous stroke, there was a significant difference between PET-positive and PET-negative patients among those with TIA as a qualifying event (average z score ϭ Ϫ1.41 vs Ϫ0.76, p ϭ 0.040). Older age and right ICA side were also significant in this model, as shown in table 3. DISCUSSION We show in a hemodynamically well-characterized cohort that cognitive impairment was independently associated with unilateral cerebral hypoperfusion in patients with carotid artery occlusive disease. Specifically, stage II hemodynamic failure, as measured by increased OEF on the side of carotid occlusion, was associated with cognitive dysfunction. By taking advantage of the 2-step enrollment in the COSS/RECON study design, we were able to establish a well-matched control group: those who met the clinical inclusion criteria of symptomatic carotid artery occlusion but who differed only by the physiologic parameter of a lack of hemodynamic failure in the hemisphere supplied by the occluded carotid artery. Additional specificity for the independent effect of the hypoperfusion was afforded by the use of a cognitive battery that emphasized the hemisphere of interest and by our stratification by clinical subtype to focus on the subset of patients who qualified for the study without having new infarction or lasting clinical deficit (patients with TIA). In showing the association between cognitive dysfunction and hemodynamic failure in those with an absence of imaging-verified ischemic damage at the time of baseline cognitive testing, we could be more confident that the cognitive effects were attributable to the hemodynamic failure. The presence of age in the model suggests that the impact of hypoperfusion on cognition was greater with increasing age.
Demonstration of a clear correlation between cerebral hypoperfusion and cognitive impairment in the setting of carotid artery disease has been elusive, in part because those with carotid artery disease share vascular risk factors with patients who have no large vessel disease. 17, 18 Both sets of patients may have microinfarcts and other ischemic lesions, which are associated with cognitive decline. [18] [19] [20] [21] Several case series have shown cognitive dysfunction in patients with carotid artery stenosis or occlusion [22] [23] [24] and even showed reversibility of cognitive impairment with revascularization, [2] [3] [4] but an independent association with hypoperfusion has been difficult to establish. With the refinement of PET and other hemodynamic techniques in the 1980s, it became possible to quantify cerebral hemodynamics in terms of CBF, oxygen and glucose utilization, and cerebral autoregulatory capacity. [25] [26] [27] In addition, unlike methods that measured CBF alone, the PET method allowed functionally important hypoperfusion resulting from carotid occlusive disease to be distinguished from hypoperfusion due simply to reduced metabolic demands of damaged (infarcted) tissue. Using quantitative PET methods, we were able to define more precisely cerebral hemodynamic status. Current hemodynamic theory holds that as perfusion pressure falls, CBF is maintained by autoregulatory vasodilation of cerebral arterioles. As perfusion pressure falls further, CBF begins to decrease and a metabolic compensation occurs as the OEF increases to maintain tissue oxygen metabolism. This stage II hemodynamic failure, sometimes referred to as misery perfusion, 28 is thought to represent a vulnerable hemodynamic state in which any further drop in perfusion will produce ischemia. Reduced cerebrovascular resistance (CVR) on the side of carotid occlusion or stenosis indicates preexisting autoregulatory vasodilation and has been associated with cognitive impairment in patients with asymptomatic carotid stenosis at baseline 29 and with cognitive improvement when the impaired CVR is reversed after endarterectomy. 30 Other studies have shown a lack of association between CVR and cognitive impairment. 31 In an important single case study, cerebral hemodynamic measures were assessed in a 55-year-old man with bilateral ICA occlusions presenting with subacute onset of severe behavioral and cognitive changes. 32 Quantitative CBF and PET studies showed a 40%-50% reduction in blood flow and metabolism. After EC-IC bypass, there were significant increases in CBF and metabolism, accompanied by neuropsychological improvement. In a larger case series, among 25 patients with mild stroke or TIA, unilateral ICA or middle cerebral artery occlusion, and increased OEF by PET, verbal and performance IQ and full-scale IQ scores were all impaired before EC-IC bypass. After intervention, there was a significant increase in IQ scores that was correlated in a multivariable analysis with measures of CBF and metabolism. 33 The current study supports a mechanistic basis for what has been reported mostly as observational cases and clinical case series. The notion that reduction of CBF in a hemisphere fed by an occluded carotid artery is sufficient to produce significant cognitive dysfunction in the absence of acute infarction has until now been inadequately demonstrated. One limitation in our study is that we did not have imaging results for all our patients to know whether the topography and distribution of preexisting ischemic changes were different between those with normal vs abnormal OEF. Although increased OEF was shown to be independently associated with cognitive impairment in this study, it could be that previous strokes, which did not differ categorically between those with and without increased OEF, had different distributions or morphologies that could account for differences in cognitive function. 34, 35 In addition, increased OEF can cause unihemispheric neuronal loss without infarction, 36 which could explain our data as well. If either differences in previous stroke topography or differences in selective neuronal loss were present in our cohort, then improvement in OEF might not result in improved cognition. The question of whether cognitive dysfunction is reversible when the hemodynamic impairment is treated will need to await the main results of the RECON trial. Nonetheless, by investigating the association between cerebral hemodynamic failure and cognitive impairment using reliable, quantitative methods for physiologic and behavioral measurements and comparing with an appropriate control group, we have been able to show the hemodynamic effects of the carotid occlusive disease on cognition, thus establishing the substrate upon which a treatment, in this case EC-IC bypass, may be meaningfully tested.
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